Recurrent Prostate Cancer Diagnostics with 18F-PSMA-1007 PET/CT: A Systematic Review of the Current State

dc.contributor.authorSaule, Laura
dc.contributor.authorRadzina, Maija
dc.contributor.authorLiepa, Mara
dc.contributor.authorRoznere, Lilita
dc.contributor.authorLioznovs, Andrejs
dc.contributor.authorRatniece, Madara
dc.contributor.authorMamis, Edgars
dc.contributor.authorVjaters, Egils
dc.contributor.institutionDepartment of Radiology
dc.date.accessioned2022-12-30T10:00:02Z
dc.date.available2022-12-30T10:00:02Z
dc.date.issued2022-12-15
dc.descriptionFunding Information: This research was funded by Latvian Council of Science, grant number: lzp-2019/1-0056 “Impact of Targeted Molecular Imaging with 18F-PSMA-1007 and 68Ga-PSMA-11 PET/CT in Multimodal Evaluation of Recurrent Prostate Cancer”. This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101008571 (PRISMAP). This document reflects only the view of the author(s). The funding agenc(y/ies) is/are not responsible for any use that may be made of the information it contains. Publisher Copyright: © 2022 by the authors.
dc.description.abstractBACKGROUND: Early diagnosis of recurrent prostate cancer is a cornerstone for further adequate therapy planning. Therefore, clinical practice and research still focuses on diagnostic tools that can detect prostate cancer in early recurrence when it is undetectable in conventional diagnostic imaging. 18F-PSMA-1007 PET/CT is a novel method to evaluate patients with biochemical recurrent PCa. The aim of this review was to evaluate the role of 18F-PSMA-1007 PET/CT in prostate cancer local recurrence, lymph node metastases and bone metastases detection. METHODS: Original studies, reviews and five meta-analyses were included in this article. A total of 70 studies were retrieved, 31 were included in the study. RESULTS: All patients described in the studies underwent 18F-PSMA-1007 PET/CT. The administered 18F-PSMA-1007 individual dose ranged from 159 ± 31 MBq to 363.93 ± 69.40 MBq. Results showed that 18F-PSMA-1007 PET/CT demonstrates a good detection rate in recurrent prostate cancer. CONCLUSIONS: 18F-PSMA-1007 PET/CT appears to achieve reliable performance in detecting recurrent prostate cancer. The high detection rate of 18F-PSMA-1007 PET/CT in recurrent prostate cancer was confirmed, especially in local recurrence and small lymph nodes with non-specific characteristics on conventional diagnostic imaging methods. However, several authors emphasize some limitations for this tracer-for example, non-specific uptake in bone lesions that can mimic bone metastases.en
dc.description.statusPeer reviewed
dc.format.extent15
dc.format.extent2467430
dc.identifier.citationSaule, L, Radzina, M, Liepa, M, Roznere, L, Lioznovs, A, Ratniece, M, Mamis, E & Vjaters, E 2022, 'Recurrent Prostate Cancer Diagnostics with 18F-PSMA-1007 PET/CT: A Systematic Review of the Current State', Diagnostics, vol. 12, no. 12, 3176, pp. 1-15. https://doi.org/10.3390/diagnostics12123176
dc.identifier.doi10.3390/diagnostics12123176
dc.identifier.issn2075-4418
dc.identifier.otherunpaywall: 10.3390/diagnostics12123176
dc.identifier.urihttps://dspace.rsu.lv/jspui/handle/123456789/9977
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=85144848636&partnerID=8YFLogxK
dc.language.isoeng
dc.relation.ispartofDiagnostics
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectPET/CT
dc.subjectprostate cancer
dc.subjectrecurrence
dc.subject18F-PSMA-1007
dc.subject3.2 Clinical medicine
dc.subject1.1. Scientific article indexed in Web of Science and/or Scopus database
dc.subjectSDG 3 - Good Health and Well-being
dc.titleRecurrent Prostate Cancer Diagnostics with 18F-PSMA-1007 PET/CT: A Systematic Review of the Current Stateen
dc.type/dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/systematicreview

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Recurrent_Prostate_Cancer_Diagnostics_with.pdf
Size:
2.35 MB
Format:
Adobe Portable Document Format